Compare MIAX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIAX | CELC |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | 439 | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | MIAX | CELC |
|---|---|---|
| Price | $44.91 | $120.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $47.00 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 1.2M | 676.0K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.20 | $720.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.20 | $9.64 |
| 52 Week High | $51.38 | $127.34 |
| Indicator | MIAX | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 56.23 |
| Support Level | $41.36 | $98.31 |
| Resistance Level | $45.70 | N/A |
| Average True Range (ATR) | 1.28 | 5.17 |
| MACD | 0.58 | 0.66 |
| Stochastic Oscillator | 91.82 | 64.88 |
Miami International Holdings Inc is engaged in operating regulated financial marketplaces across multiple asset classes using proprietary technology platforms. The company operates exchange markets for options, equities, futures, and international listings through its MIAX Exchanges, MIAX Futures Exchange, and the Bermuda Stock Exchange. The company operates through four reportable segments: Options, which provides trading and market data services for listed equity and ETP options; Equities, which provides trading services for U.S. equities and ETPs; Futures, which provides futures trading and clearing services through MIAX Futures; and International, which provides listing services for capital market instruments through the Bermuda Stock Exchange and The International Stock Exchange.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.